中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (3): 811-812.doi: 10.4103/NRR.NRR-D-23-02094

• 观点:退行性病与再生 • 上一篇    下一篇

多发性硬化正处于检查点:推进该项目

  

  • 出版日期:2025-03-15 发布日期:2024-06-26

Multiple sclerosis is at a checkpoint: advancing the program

Brandon C. Smith, Jessica L. Williams*   

  1. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA (Smith BC, Williams JL)
    Department of Biological, Geological, and Environmental Sciences, Cleveland State University, Cleveland, OH, USA (Smith BC)
  • Online:2025-03-15 Published:2024-06-26
  • Contact: Jessica L. Williams, PhD, williaj39@ccf.org.

摘要: https://orcid.org/0000-0002-9801-9580 (Jessica L. Williams)

Abstract: Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system (CNS). Patients with MS experience sensory and motor function loss due to myelin and/or axon damage perpetuated by infiltrating immune cells (Hauser and Cree, 2020). Before modern therapies, most patients experienced heightened symptoms followed by partial recovery. A significant proportion of these patients would then advance to a progressive disease state which features continual neuroaxonal loss and less frequent recovery (Degenhardt et al., 2009). However, with the advancement of several treatment strategies, the view of MS within the field has also begun to evolve. Current therapies reduce or eliminate the occurrence of relapse, yet there is still progression independent of relapse activity (Tur et al., 2023). These treatments prevent relapses primarily by limiting new lesions formed by the infiltration of T cells, B cells, and macrophages from the periphery, inciting inflammation and myelin damage. Newly formed lesions are often called active lesions due to their inflammatory nature. Ocrelizumab, which depletes CD20+ B cells, and Natalizumab, which targets the α4-integrin subunit of α4β1 to hinder lymphocytes from entering the CNS, are examples of commonly used treatments to prevent active lesion formation (Hauser and Cree, 2020).